Durability of XBB.1.5 Vaccines against Omicron Subvariants
- PMID: 38810167
- PMCID: PMC11197991
- DOI: 10.1056/NEJMc2402779
Durability of XBB.1.5 Vaccines against Omicron Subvariants
Figures

Similar articles
-
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.Emerg Microbes Infect. 2024 Dec;13(1):2387447. doi: 10.1080/22221751.2024.2387447. Epub 2024 Aug 19. Emerg Microbes Infect. 2024. PMID: 39082740 Free PMC article.
-
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.J Virol. 2024 Oct 22;98(10):e0052824. doi: 10.1128/jvi.00528-24. Epub 2024 Sep 4. J Virol. 2024. PMID: 39230305 Free PMC article.
-
Plasma Neutralization of the SARS-CoV-2 Omicron Variant.N Engl J Med. 2022 Feb 10;386(6):599-601. doi: 10.1056/NEJMc2119641. Epub 2021 Dec 30. N Engl J Med. 2022. PMID: 35030645 Free PMC article. No abstract available.
-
Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.Hum Vaccin Immunother. 2025 Dec;21(1):2473795. doi: 10.1080/21645515.2025.2473795. Epub 2025 Mar 7. Hum Vaccin Immunother. 2025. PMID: 40051347 Free PMC article. Review.
-
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.Sci Adv. 2021 Mar 19;7(12):eabe8065. doi: 10.1126/sciadv.abe8065. Print 2021 Mar. Sci Adv. 2021. PMID: 33608249 Free PMC article. Review.
Cited by
-
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.Vaccines (Basel). 2024 Jul 15;12(7):774. doi: 10.3390/vaccines12070774. Vaccines (Basel). 2024. PMID: 39066413 Free PMC article.
-
Reduced cross-protective potential of Omicron compared to ancestral SARS-CoV-2 spike vaccines against potentially zoonotic coronaviruses.Npj Viruses. 2024 Nov 21;2(1):58. doi: 10.1038/s44298-024-00067-9. Npj Viruses. 2024. PMID: 40295830 Free PMC article.
-
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.Nat Commun. 2024 Dec 30;15(1):10778. doi: 10.1038/s41467-024-55087-z. Nat Commun. 2024. PMID: 39738039 Free PMC article. Clinical Trial.
-
Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up.PLoS One. 2025 Jun 3;20(6):e0325269. doi: 10.1371/journal.pone.0325269. eCollection 2025. PLoS One. 2025. PMID: 40460407 Free PMC article.
-
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United States.Open Forum Infect Dis. 2024 Nov 26;11(12):ofae695. doi: 10.1093/ofid/ofae695. eCollection 2024 Dec. Open Forum Infect Dis. 2024. PMID: 39691287 Free PMC article.
References
-
- Food and Drug Administration. FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. Press release, September 11, 2023 (https://www.fda.gov/news-events/press-announcements/fda-takes-action-upd...),
-
- Food and Drug Administration. FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants. Pres release, October 03, 2023 (https://www.fda.gov/news-events/press-announcements/fda-authorizes-updat...).
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical